

**The spectrum of COVID-19-associated dermatologic manifestations:
an international registry of 716 patients from 31 countries**

Authors: Esther E. Freeman MD PhD,^{1,2} Devon E. McMahon BA,¹ Jules B. Lipoff MD,³ Misha Rosenbach MD,³ Carrie Kovarik MD,³ Seemal R. Desai MD,⁴ Joanna Harp MD,⁵ Junko Takeshita MD PhD MSCE,³ Lars E. French MD,^{6,7} Henry W. Lim MD,⁸ Bruce H. Thiers MD,⁹ George J. Hruza MD MBA,¹⁰ Lindy P. Fox MD¹¹

¹Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; ²Medical Practice Evaluation Center, Mongan Institute, Massachusetts General Hospital, Boston, MA; ³Department of Dermatology, University of Pennsylvania, Philadelphia, PA; Department of Dermatology; ⁴The University of Texas Southwestern Medical Center, Dallas, Texas, Innovative Dermatology, Plano, Texas; ⁵Department of Dermatology, Weill Cornell Medicine, New York, NY; ⁶Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany; Department of Dermatology, ⁷Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami, Miller School of Medicine, ⁸Department of Dermatology, Henry Ford Health System, Detroit, MI, USA; ⁹Department of Dermatology and Dermatologic Surgery, Medical University of SC, Charleston, SC; ¹⁰Department of Dermatology, St. Louis University, St. Louis, MO; ¹¹Department of Dermatology, University of California San Francisco, San Francisco, CA

Corresponding Author:

Esther Freeman, MD, PhD

Massachusetts General Hospital

55 Fruit St, Boston, MA 02114

Email: efreeman@mgh.harvard.edu

Keywords: COVID-19; SARS-CoV-2; dermatology; public health; registry; pernio; COVID toes; morbilliform; urticarial; vesicular; macular erythema; retiform purpura; global health

Funding: None

Disclosures: Drs. Freeman, Lipoff, Rosenbach, Kovarik, Desai, Takeshita, Hruza Thiers and Fox are part of the American Academy of Dermatology (AAD) COVID-19 Ad Hoc Task Force. Dr. French is president and Dr. Lim is board member of the International League of Dermatological Societies (ILDS). Dr. Hruza is immediate past president of the AAD. Dr. Thiers is the President of the AAD.

Ethics: The registry was reviewed by the Partners Healthcare (MGH) Institutional Review Board (IRB) and was determined to not meet the definition of Human Subjects Research.

Key Points

Question: What are the cutaneous manifestations associated with COVID-19 and do they provide insight into the pathophysiology or prognosis?

Findings: In this international registry-based case series of 716 patients representing 31 countries, the most common dermatologic morphologies encountered in the 171 COVID-19 confirmed case included morbilliform, pernio-like, urticarial, macular erythema, vesicular, papulosquamous, and retiform purpura. Retiform purpura was seen exclusively in critically ill, hospitalized patients.

Meaning: COVID-19 is associated with a spectrum of skin findings in affected patients. These cutaneous manifestations may vary depending on the severity of COVID-19.

Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has associated cutaneous manifestations.¹ Case series have thus far documented lesions that are pernio-like,²⁻⁶ erythematous macules or papules,⁵⁻⁷ urticarial,^{7,8} morbilliform,⁸ varicelliform,⁵⁻⁹ and papulosquamous.¹⁰ Petechial eruptions,^{8,11} livedo reticularis-like rashes,^{5,8} purpuric lesions,⁵ and acro-ischemic lesions¹² and retiform purpura¹³ have been reported less frequently. The timing of these varied eruptions in the disease course remains unclear, as do any potential associations between morphological subtypes with different COVID-19-associated syndromes, disease courses, and/or outcomes.

Methods: In collaboration with the American Academy of Dermatology (AAD) and International League of Dermatologic Societies (ILDS), we established an international registry to collect cases of COVID-19 with cutaneous associations (www.aad.org/covidregistry); the registry is open to medical professionals only. No protected health information was collected, and all data was de-identified. The registry collected information on COVID-19 diagnosis type (suspected vs laboratory-confirmed), patient demographics, comorbidities, details regarding the patients' new onset dermatologic condition, timing of dermatologic condition onset, information from skin biopsy reports when available, COVID-19 symptoms, and outcomes, including hospitalization, oxygen requirements, ventilator requirements, and deaths. All suspected or laboratory-confirmed COVID-19 cases, with new onset dermatologic findings, were eligible for inclusion in initial analysis. A sub-group analysis was performed restricted to lab-confirmed cases.

Results: The registry collected 716 cases of new-onset dermatologic symptoms in patients with suspected or confirmed COVID-19 from April 8 to May 17, 2020. Cases came from 31 countries with most (89%) from the United States. Dermatologists entered most of the cases (54%). Median patient age was 30 years (IQR 19-49). Of the 171 patients in the registry with laboratory-confirmed COVID-19, the most common cutaneous morphologies, in order of frequency, were morbilliform, pernio-like, urticarial, macular erythema, vesicular, papulosquamous, and retiform purpura. In general, lesions tended to occur after (64%) or concurrently (15%) with other COVID-19 symptoms. Retiform purpura appeared in patients with the most severe disease course, presenting exclusively in very ill, hospitalized patients. Skin biopsies were reviewed for 15 patients.

Conclusions and Relevance: This study highlights the array of cutaneous manifestations associated with COVID-19 diagnoses. Many morphologies were non-specific, while others may allow insight into potential immune or inflammatory pathways in COVID-19 pathophysiology. These cutaneous manifestations may vary depending on the severity of COVID-19, with retiform purpura exclusively reported in hospitalized patients.

Acknowledgements

We appreciate all the healthcare providers worldwide who entered cases in this registry. More detailed acknowledgements will appear in the published version of this paper.

References:

1. Jia JL, Kamceva M, Rao SA, Linos E. Cutaneous Manifestations of COVID-19: A Preliminary Review. *J Am Acad Dermatol* 2020.
2. Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, et al. Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak. *J Am Acad Dermatol* 2020.
3. Piccolo V, Neri I, Filippeschi C, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. *J Eur Acad Dermatol Venereol* 2020.
4. Recalcati S, Barbagallo T, Frasin LA, et al. Acral cutaneous lesions in the Time of COVID-19. *J Eur Acad Dermatol Venereol* 2020.
5. Bouaziz JD, Duong T, Jachiet M, et al. Vascular skin symptoms in COVID-19: a french observational study. *J Eur Acad Dermatol Venereol* 2020.
6. Galvan Casas C, Catala A, Carretero Hernandez G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. *Br J Dermatol* 2020.
7. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol* 2020.
8. de Masson A, Bouaziz JD, Sulimovic L, et al. Chilblains are a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France. *J Am Acad Dermatol* 2020.
9. Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. *J Am Acad Dermatol* 2020.
10. Sanchez A, Sohier P, Benghanem S, et al. Digitate Papulosquamous Eruption Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *JAMA Dermatol* 2020.
11. Diaz-Guimaraens B, Dominguez-Santas M, Suarez-Valle A, et al. Petechial Skin Rash Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *JAMA Dermatol* 2020.
12. Zhang Y, Cao W, Xiao M, et al. [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia]. *Zhonghua Xue Ye Xue Za Zhi* 2020;41:E006.
13. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. *Transl Res* 2020.